<span>Li-3124-SOT19.pdf</span>
March 10, 2019

Li-3124-SOT19.pdf

SOT 2019 - Clonidine is approved for therapy of attention-deficit hyperactivity disorder (ADHD) that is one of the most common neurobehavioral problems mainly afflicting children and youth between 6 and 17 years of age with a high modality from 2% to 18% in USA.
<span>Speed Your Neuroscience Trial</span>
March 15, 2019

Speed Your Neuroscience Trial

Developing a drug to treat diseases of Neuroscience is extraordinarily challenging both clinically and operationally. Challenges can include patient heterogeneity, a lack of biomarkers, subjective and insensitive rating scales, enrolling patients at the earliest stage in their disease progression and lengthy trial durations.